Diurnal effects of fluoxetine and naloxone on the human hypothalamic- pituitary-adrenal axis

Clinical and Experimental Pharmacology and Physiology

Volumn 24, Issue 6, 1997, Pages 421-423

  Torpy, D J ^a,b   Grice, J E ^a   Hockings, G I ^a   Walters, M M ^a   Crosbie, G V ^a   Jackson, R V ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

adrenocorticotropic hormone; argipressin; corticotropin releasing hormone; fluoxetine; humans; hydrocortisone; hypothalamo hypophyseal system; naloxone; pituitary gland (anterior); pituitary adrenal system

Indexed keywords

ARGIPRESSIN; CORTICOTROPIN; FLUOXETINE; HYDROCORTISONE; NALOXONE;

ADULT; ARTICLE; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOTROPIN BLOOD LEVEL; CORTICOTROPIN RELEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HORMONAL REGULATION; HUMAN; HUMAN EXPERIMENT; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SEROTONINERGIC SYSTEM;

EID: 0030997676     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1681.1997.tb01213.x     Document Type: Article

References (21)

1. Bruni JF, Hawkins RL, Yen SSC. Serotonergic mechanism in the control of β-endorphin and ACTH release in male rats. Life Sci. 1982; 30: 1247-54.
2. Fuller RW. Serotonergic stimulation of pituitary-adrenocortical function in rats. Neuroendocrinology 1981; 32: 118-27.
3. Gibbs DM, Vale W. Effect of the serotonin reuptake inhibitor fluoxetine on corticotropin-releasing factor and vasopressin secretion into hypophysial portal blood. Brain Res. 1983; 280: 176-9.
4. Lewis DA, Sherman BM. Serotonergic stimulation of adrenocorticotropin secretion in man. J. Clin. Endocrinol. Metab. 1984; 58: 458-62.
5. Grice JE, Jackson AJ, Penfold PJ, Jackson RV. Adrenocorticotropin hyperresponsiveness in myotonic dystrophy following fenfluramine administration. J. Neuroendocrinol. 1991; 3: 69-73.
6. Jackson RV, Grice JE, Jackson AJ, Vella RD. Potentiation of fenfluramine-induced ACTH release by naloxone. Clin. Exp. Pharmacol. Physiol. 1989; 16: 263-7.
7. Smythe GA, Gleeson RM, Stead BM. Mechanisms of 5-hydroxy-L-tryptophan-induced adrenocorticotropin release: A major role for central noradrenergic drive. Neuroendocrinology 1988; 47: 389-97.
8. Fuxe K, Farnebo LO, Hamberger B, Ogren SO. On the in vivo and in vitro actions of fenfluramine and its derivatives on central monoamine neurons, especially 5-hydroxytryptamine neurons and their relation to the anorectic activity of fenfluramine. Postgrad. Med. J. 1975; 51: 35-45.
9. Okada F, Saito Y, Fujieda T, Yamashita I. Monamine changes in the brain of rats injected with L-5-hydroxytryptophan. Nature 1972; 238: 355-6.
10. Chihara K, Kato Y, Maeda K, Matsukura S, Imura H. Suppression by cyproheptadine of human growth hormone and cortisol secretion during sleep. J. Clin. Invest. 1976; 57: 1393-402.
11. Al-Damluji S, Rees LH. The neuroendocrine control of corticotropin secretion in normal humans and in Cushing's disease. In: Collu R, Brown GM, Van Loon GR (eds). Clinical Neuroendocrinology. Blackwell Science, Oxford. 1988; Ch. 10.
12. Pijl H, Koppeschaar HPF, Willekens FLA, Frolich M, Meinders AE. The influence of serotonergic neurotransmission on pituitary hormone release in obese and non-obese females. Acta Endocrinol 1993; 128: 319-24.
13. Kletzy OA, St-Michel P, Mashchak CA, Coleman BS. Lack of effect of fluvoxamine, a new serotonin reuptake inhibitor, on hypothalamic-pituitary function. Curr. Ther. Res. 1983; 33: 394-400.
14. Bardeleben UV, Steiger A, Gerken A, Holsboer F. Effects of fluoxetine upon pharmacoendocrine and sleep-EEG parameters in normal control. Int. Clin. Psychopharmacol. 1989; 4: 1-5.
15. Petraglia F, Facchinetti F, Martignoni E, Nappi G, Volpe A, Genazzani AR. Serotoninergic agonists increase plasma levels of β-endorphin and β-lipotropin in humans. J. Clin. Endocrinol. Metab. 1984; 59: 1138-42.
16. Nicholson WE, Davis DR, Sherrel BJ, Orth DN. Rapid radioimmunoassay for corticotropin in unextracted human plasma. Clin. Chem. 1984; 30: 259-65.
17. Chrousos GP, Gold PW. The concepts of stress and stress system disorders. Overview of physical and behavioural homeostasis. JAMA 1992; 267: 1244-52.
18. Stark P, Fuller RW, Wong DT. The pharmacological profile of fluoxetine. J. Clin. Psychiatry 1985; 46: 7-13.
19. DeBellis MD, Gold PW, Geracioti TD Jr, Listwak SJ, Kling MA. Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression. Am. J. Psychiatry 1993; 150: 656-7.
20. Antoni FA. Vasopressinergic control of pituitary adrenocorticotropin secretion comes of age. Front. Neuroendocrinol. 1993; 14: 76-122.
21. Altemus M, Cizza G, Gold PW. Chronic fluoxetine treatment reduces hypothalamic vasopressin secretion in vitro. Brain Res. 1992; 593: 311-13.